|
Market Closed -
Other stock markets
|
After hours 22:32:04 | |||
| 147.23 USD | -2.93% |
|
140.32 | -4.69% |
| 09:50pm | Gilead Sciences, Inc. Increases Cash Dividend for the First Quarter of 2026, Payable on March 30, 2026 | CI |
| 09:39pm | Gilead 2026 outlooks short of Wall Street view, shares fall | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 10.78 | 10.24 | 10.46 | 9.78 | 11.03 | |||||
Return on Total Capital | 14.26 | 14.15 | 14.38 | 12.84 | 14.07 | |||||
Return On Equity % | 0.44 | 31.57 | 21.6 | 25.54 | 2.29 | |||||
Return on Common Equity | 0.6 | 31.7 | 21.71 | 25.71 | 2.28 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 85.05 | 79.76 | 79.26 | 77.8 | 78.26 | |||||
SG&A Margin | 19.88 | 19.21 | 20.79 | 20.42 | 20.87 | |||||
EBITDA Margin % | 51.43 | 48.42 | 47.93 | 46.08 | 46.79 | |||||
EBITA Margin % | 50.26 | 47.21 | 46.75 | 44.77 | 45.46 | |||||
EBIT Margin % | 45.43 | 40.91 | 40.23 | 36.15 | 37.17 | |||||
Income From Continuing Operations Margin % | 0.36 | 22.71 | 16.74 | 20.7 | 1.67 | |||||
Net Income Margin % | 0.5 | 22.8 | 16.83 | 20.89 | 1.67 | |||||
Net Avail. For Common Margin % | 0.5 | 22.8 | 16.83 | 20.89 | 1.67 | |||||
Normalized Net Income Margin | 26.66 | 23.3 | 23.27 | 21.45 | 21.71 | |||||
Levered Free Cash Flow Margin | 32.06 | 37.67 | 25.42 | 32.43 | 35.23 | |||||
Unlevered Free Cash Flow Margin | 34.55 | 39.96 | 27.56 | 34.6 | 37.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.38 | 0.4 | 0.42 | 0.43 | 0.47 | |||||
Fixed Assets Turnover | 4.58 | 4.84 | 4.69 | 4.57 | 4.86 | |||||
Receivables Turnover (Average Receivables) | 5.83 | 5.82 | 5.89 | 5.75 | 6.33 | |||||
Inventory Turnover (Average Inventory) | 2.83 | 3.35 | 3.62 | 3.65 | 3.58 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.4 | 1.27 | 1.29 | 1.43 | 1.6 | |||||
Quick Ratio | 1.19 | 1.07 | 1.04 | 1.15 | 1.33 | |||||
Operating Cash Flow to Current Liabilities | 0.72 | 0.98 | 0.81 | 0.71 | 0.9 | |||||
Days Sales Outstanding (Average Receivables) | 62.81 | 62.73 | 62.01 | 63.51 | 57.79 | |||||
Days Outstanding Inventory (Average Inventory) | 129.16 | 109.02 | 100.82 | 99.88 | 102.38 | |||||
Average Days Payable Outstanding | 64 | 51.77 | 52.98 | 42.16 | 40.99 | |||||
Cash Conversion Cycle (Average Days) | 127.97 | 119.98 | 109.85 | 121.23 | 119.17 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 176.26 | 129.53 | 121.68 | 112.79 | 141.96 | |||||
Total Debt / Total Capital | 63.8 | 56.43 | 54.89 | 53 | 58.67 | |||||
LT Debt/Equity | 160.55 | 121.86 | 110.44 | 104.33 | 131.94 | |||||
Long-Term Debt / Total Capital | 58.11 | 53.09 | 49.82 | 49.03 | 54.53 | |||||
Total Liabilities / Total Assets | 73.36 | 69 | 66.43 | 63.38 | 67.38 | |||||
EBIT / Interest Expense | 11.4 | 11.16 | 11.74 | 10.38 | 10.94 | |||||
EBITDA / Interest Expense | 13.08 | 13.36 | 14.16 | 13.41 | 13.94 | |||||
(EBITDA - Capex) / Interest Expense | 12.42 | 12.78 | 13.38 | 12.79 | 13.4 | |||||
Total Debt / EBITDA | 2.5 | 2.04 | 1.95 | 2.03 | 2.01 | |||||
Net Debt / EBITDA | 1.79 | 1.35 | 1.34 | 1.28 | 1.16 | |||||
Total Debt / (EBITDA - Capex) | 2.63 | 2.13 | 2.06 | 2.12 | 2.09 | |||||
Net Debt / (EBITDA - Capex) | 1.88 | 1.41 | 1.42 | 1.34 | 1.2 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 9.98 | 10.6 | -0.09 | -0.6 | 6.04 | |||||
Gross Profit, 1 Yr. Growth % | 18.14 | 3.72 | -0.71 | -2.44 | 6.66 | |||||
EBITDA, 1 Yr. Growth % | 18.2 | 4.12 | -6.47 | -4.3 | 12.4 | |||||
EBITA, 1 Yr. Growth % | 18.33 | 3.88 | -6.58 | -4.65 | 12.54 | |||||
EBIT, 1 Yr. Growth % | 20.12 | -0.42 | -8.03 | -10.51 | 15.2 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -98.34 | 6.87K | -26.37 | 22.93 | -91.45 | |||||
Net Income, 1 Yr. Growth % | -97.72 | 4.96K | -26.23 | 23.37 | -91.53 | |||||
Normalized Net Income, 1 Yr. Growth % | 16.95 | -3.35 | -7.16 | -8.17 | 13.75 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -97.68 | 4.94K | -26.17 | 23.63 | -91.56 | |||||
Accounts Receivable, 1 Yr. Growth % | 36.57 | -8.16 | 6.32 | -2.45 | -5.15 | |||||
Inventory, 1 Yr. Growth % | 82.54 | -3.86 | -6.86 | 18.58 | -4.31 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.57 | 0.89 | 5.6 | -1.37 | 0.53 | |||||
Total Assets, 1 Yr. Growth % | 11 | -0.67 | -7.04 | -1.66 | -5.04 | |||||
Tangible Book Value, 1 Yr. Growth % | -598.31 | -10.05 | -22.93 | -25.26 | -25.16 | |||||
Common Equity, 1 Yr. Growth % | -19.19 | 15.75 | 0.81 | 7.5 | -15.34 | |||||
Cash From Operations, 1 Yr. Growth % | -10.67 | 39.37 | -20.31 | -11.75 | 35.25 | |||||
Capital Expenditures, 1 Yr. Growth % | -21.21 | -10.92 | 25.73 | -19.64 | -10.6 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 58.53 | 26.57 | -32.03 | 27.03 | 19.68 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 51.93 | 24.82 | -30.56 | 25 | 18.62 | |||||
Dividend Per Share, 1 Yr. Growth % | 7.94 | 4.41 | 2.82 | 2.74 | 2.67 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 5.63 | 10.29 | 5.12 | -0.35 | 2.66 | |||||
Gross Profit, 2 Yr. CAGR % | 10.25 | 10.69 | 1.48 | -1.58 | 2.01 | |||||
EBITDA, 2 Yr. CAGR % | 8.8 | 10.94 | 2.53 | -5.47 | 1.43 | |||||
EBITA, 2 Yr. CAGR % | 8.71 | 10.87 | 2.45 | -5.7 | 1.24 | |||||
EBIT, 2 Yr. CAGR % | 9.84 | 9.37 | 0.07 | -9.36 | -1.32 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -87.23 | 7.52 | 616.26 | -4.86 | -67.58 | |||||
Net Income, 2 Yr. CAGR % | -84.98 | 7.51 | 511.01 | -4.6 | -67.67 | |||||
Normalized Net Income, 2 Yr. CAGR % | 9.56 | 6.31 | -0.57 | -7.77 | -0.82 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -84.68 | 8.09 | 509.91 | -4.46 | -67.69 | |||||
Accounts Receivable, 2 Yr. CAGR % | 21.26 | 12 | -1.18 | 1.84 | -3.81 | |||||
Inventory, 2 Yr. CAGR % | 43.79 | 32.47 | -5.37 | 5.09 | 6.52 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 18.37 | 4.66 | 3.22 | 2.05 | -0.43 | |||||
Total Assets, 2 Yr. CAGR % | 3.65 | 5.01 | -3.9 | -4.38 | -3.36 | |||||
Tangible Book Value, 2 Yr. CAGR % | 287.74 | 111.72 | -16.74 | -24.1 | -25.21 | |||||
Common Equity, 2 Yr. CAGR % | -7.75 | -3.29 | 8.02 | 4.1 | -4.6 | |||||
Cash From Operations, 2 Yr. CAGR % | -1.39 | 11.58 | 5.39 | -16.14 | 9.25 | |||||
Capital Expenditures, 2 Yr. CAGR % | -16.13 | -16.23 | 5.83 | 0.52 | -15.24 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 7.21 | 43.54 | -6.69 | -7.16 | 20.86 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 6.22 | 39.41 | -6.38 | -6.91 | 19.52 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.22 | 6.16 | 3.61 | 2.78 | 2.7 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -1.84 | 7.26 | 6.71 | 3.17 | 1.74 | |||||
Gross Profit, 3 Yr. CAGR % | -1.14 | 8.03 | 6.75 | 0.16 | 1.1 | |||||
EBITDA, 3 Yr. CAGR % | -6.25 | 7.21 | 6.78 | 0.15 | -1.28 | |||||
EBITA, 3 Yr. CAGR % | -6.49 | 7.07 | 6.74 | -0.03 | -1.44 | |||||
EBIT, 3 Yr. CAGR % | -7.39 | 6.31 | 5.53 | -3.65 | -3.61 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -73.24 | 4.33 | -5.23 | 298.05 | -57.38 | |||||
Net Income, 3 Yr. CAGR % | -70.16 | 4.5 | -5.18 | 258.45 | -57.44 | |||||
Normalized Net Income, 3 Yr. CAGR % | -7.95 | 5.07 | 4.09 | -3.24 | -2.98 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -69.68 | 5.74 | -4.81 | 258.27 | -57.44 | |||||
Accounts Receivable, 3 Yr. CAGR % | 8.3 | 10.53 | 10.07 | -1.61 | -0.54 | |||||
Inventory, 3 Yr. CAGR % | 28.08 | 25.73 | 17.8 | 2.02 | 1.86 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 19.43 | 12.23 | 4.97 | 1.66 | 1.54 | |||||
Total Assets, 3 Yr. CAGR % | -0.9 | 2.19 | 0.83 | -3.16 | -4.6 | |||||
Tangible Book Value, 3 Yr. CAGR % | 204.35 | 138.25 | 51.17 | -19.68 | -24.46 | |||||
Common Equity, 3 Yr. CAGR % | -3.79 | -0.5 | -1.94 | 7.85 | -2.83 | |||||
Cash From Operations, 3 Yr. CAGR % | -11.78 | 10.66 | -0.26 | -0.67 | -1.66 | |||||
Capital Expenditures, 3 Yr. CAGR % | 3.28 | -14.43 | -4.08 | -3.45 | -3.33 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -9.06 | 14.31 | 11.58 | 3.35 | -0.24 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -8.74 | 13.01 | 10.23 | 3.03 | -0.27 | |||||
Dividend Per Share, 3 Yr. CAGR % | 9.35 | 7.6 | 5.03 | 3.32 | 2.74 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -5.43 | -2.12 | 0.88 | 4.15 | 5.08 | |||||
Gross Profit, 5 Yr. CAGR % | -6.01 | -3.58 | -0.1 | 4.08 | 4.83 | |||||
EBITDA, 5 Yr. CAGR % | -11.43 | -7.21 | -3.23 | 3.1 | 4.61 | |||||
EBITA, 5 Yr. CAGR % | -11.71 | -7.51 | -3.42 | 2.94 | 4.51 | |||||
EBIT, 5 Yr. CAGR % | -12.76 | -9.17 | -4.92 | 1.06 | 2.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -65.46 | -14.39 | -0.34 | 0.55 | -38.29 | |||||
Net Income, 5 Yr. CAGR % | -63.15 | -14.34 | -0.16 | 0.76 | -38.34 | |||||
Normalized Net Income, 5 Yr. CAGR % | -13.43 | -10.32 | -5.54 | 1.19 | 2.1 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -61.72 | -13.09 | 0.73 | 1.53 | -38.21 | |||||
Accounts Receivable, 5 Yr. CAGR % | -3.53 | -0.09 | 4.4 | 6.97 | 4.29 | |||||
Inventory, 5 Yr. CAGR % | -2.95 | 0.39 | 13.47 | 17.03 | 13.15 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 19.79 | 14.6 | 12.66 | 8.04 | 2.78 | |||||
Total Assets, 5 Yr. CAGR % | 5.75 | 3.59 | -2.11 | -0.49 | -0.87 | |||||
Tangible Book Value, 5 Yr. CAGR % | 26.48 | 18.83 | 81.22 | 50.77 | 14.08 | |||||
Common Equity, 5 Yr. CAGR % | -0.36 | 2.21 | 0.77 | 1.32 | -3.01 | |||||
Cash From Operations, 5 Yr. CAGR % | -17.41 | -7.76 | -5.28 | -0.96 | 3.44 | |||||
Capital Expenditures, 5 Yr. CAGR % | -2.74 | -4.99 | 4.29 | -8.74 | -8.71 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -12.28 | -6.31 | -8 | 5.01 | 15.2 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -11.45 | -5.98 | -7.7 | 4.42 | 13.86 | |||||
Dividend Per Share, 5 Yr. CAGR % | 16.09 | 9.07 | 7.02 | 5.64 | 4.1 |
- Stock Market
- Equities
- GILD Stock
- Financials Gilead Sciences, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















